Blog

Learn how multivalent and bispecific VHH antibodies are engineered, their advantages, applications, and key challenges in therapeutic development.

April 2026 activity saw consolidation in the ADC space, continued expansion of next-generation antibody formats (including DACs and trispecifics), and strong financing for platform-driven oncology innovation. Strategic M&A and high-value partnerships highlighted sustained interest in complex biologics and targeted delivery technologies.

Read on for key trends talked about during the conference: Antibody Therapeutics Xchange - Boston 2026, held on April 28.

Explore VHH antibody humanization strategies, challenges, and validation methods to reduce immunogenicity while preserving stability and binding.

The BioPlus Global Forum 2026, held alongside AACR, highlighted emerging antibody targets, next-generation modalities, and shifting global development dynamics, with a strong focus on GI oncology, early-stage innovation, and the growing influence of China in clinical strategy.

Read a recap of the AACR Annual Meeting 2026, held in San Diego, CA, from April 17–22, 2026, bringing together global leaders in cancer research, drug development, and translational medicine. AACR showcased advances in tumor biology, immunotherapy, precision medicine, and emerging therapeutic modalities, with a strong focus on translating mechanistic insights into next-generation cancer therapies.

IMMUNOLOGY2026 was held in Boston, MA, from April 15-19, 2026. The meeting highlighted a broad spectrum of scientific progress, from fundamental insights into immune cell biology to translational innovations shaping vaccines, antibody therapeutics, and immune-mediated disease treatment, under the central theme of translating discovery into clinical impact.

Polyclonal antibodies (pAbs) represent one of the earliest forms of antibody therapeutics, with clinical use dating back to serum therapies for infectious diseases such as diphtheria and tetanus in the late 19th century. Now, they are used in a wide range of modern therapeutics.

A new generation of biotech companies is rapidly advancing the antibody landscape, fueled by strong early-stage funding and a focus on differentiated therapeutic strategies. Across modalities, from bispecific antibodies and ADCs to single-domain antibodies, shuttle systems, and half-life extension, these emerging players are not only expanding the scope of what antibodies can target, but also how they function in complex disease settings.

March 2026 saw a surge in antibody dealmaking, focusing on T-cell engagers and autoimmune applications, alongside advancements in targeted protein degradation.

Clinical drug development remains associated with a high failure rate, primarily to lack of efficacy, unmanageable toxicity, and suboptimal drug-like properties. These data indicate that, despite extensive optimization workflows, current strategies do not fully capture all determinants of clinical success.

Read on for the key trends of the NextGen Biomed 2026 conference held in London from March 24-25, featuring discussions across the entire value chain, from antibody engineering advancements to sustainable practices in TIDES chemistry!